Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA3 | P07451 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361971 | 1.00 | LMNA (0.58) | LMNACA12CA1CA2CA3 | |
| SCHEMBL18586432 | 0.85 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8772759 | 0.84 | LMNA (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL17241030 | 0.81 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL30174478 | 0.79 | LMNA (0.58) | LMNACA12CA1CA2CA3 | |
| SCHEMBL9935474 | 0.79 | LMNA (0.62) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2372821 | 0.79 | LMNA (0.62) | LMNACA12CA1CA2CA3 | |
| SCHEMBL5315883 | 0.79 | LMNA (0.58) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8371409 | 0.79 | LMNA (0.58) | LMNACA12CA1CA2CA3 | |
| SCHEMBL995319 | 0.79 | LMNA (0.58) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745471-B2 | Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide | CHEMAGIS LTD. (IL) | 2010-06-29 | — | — | US | claimed |
| US-20060014814-A1 | Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide | CHEMAGIS LTD. (IL) | 2006-01-19 | — | — | US | claimed |
| EP-4252755-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2025-05-14 | — | — | EP | disclosed |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| CN-119569706-A | Therapeutic compounds | 希四克斯探索有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-112996785-B | Therapeutic compounds | 希四克斯探索有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-12098148-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2024-09-24 | — | — | US | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| EP-3192792-B1 | AMINOSULFONYL-BASED COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU VIGONVITA LIFE SCIENCES CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| US-6677458-B2 | REACTING 4-HYDROXY-COUMARIN WITH HYDROXYL-AMINE IN THE PRESENCE OF A BASE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-01-13 | — | — | US | disclosed |
| US-20020183525-A1 | Process for the preparation of 1,2-benzisoxazole-3-acetic acid | TEVA PHARMACEUTICALS USA, INC. | 2002-12-05 | — | — | US | disclosed |
| EP-0755384-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028391-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| EP-0298921-B1 | 1,2-BENZISOXAZOLES AND 1,2-BENZISOTHIAZOLES | CIBA-GEIGY AG (CH) | 1992-12-23 | — | — | EP | disclosed |
| US-4957931-A | ANTICONVULSANTS, TREATMENT OF EPILEPSY | CIBA-GEIGY CORPORATION (US) | 1990-09-18 | — | — | US | disclosed |
| US-4859691-A | Certain 1,2-benzisoxazole derivatives | CIBA-GEIGY CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0298921-A1 | 1,2-Benzisoxazoles and 1,2-benzisothiazoles | CIBA-GEIGY AG (CH) | 1989-01-11 | — | — | EP | disclosed |
| US-4172896-A | ANTICONVULSANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1979-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014814-A1 | Derivatives of 1,2-benzisoxazole-3-methane sulfonic acid as novel intermediates for the synthesis of zonisamide | ZP1, CA3, CYP4Z1 | LMNA 3346/4885CA12 585/4885CA1 37/4885 |
| US-20020183525-A1 | Process for the preparation of 1,2-benzisoxazole-3-acetic acid | HAO2, CYP2S1, CYP4X1 | LMNA 2783/4885CA12 705/4885CA1 154/4885 |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | LMNA 1602/4885CA12 4796/4885CA1 4870/4885 |
| US-12098148-B2 | Therapeutic compounds | NFE2L2, KEAP1, NQO1 | LMNA 1602/4885CA12 4796/4885CA1 4870/4885 |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | LMNA 1602/4885CA12 4796/4885CA1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.